Baird Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Key Highlights
- ➤Nasdaq notified Baird Medical (BDMD) of minimum bid-price deficiency
- ➤180-day compliance period runs through May 3, 2027
- ➤Shares continue trading uninterrupted on Nasdaq Capital Market
- ➤Compliance requires $1.00 closing bid for ten consecutive business days
- ➤Failure could lead to an additional grace period or delisting
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated November 2, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This notification does not result in the delisting of the Company’s shares, and Baird Medical’s shares will continue to trade, uninterrupted, on the Nasdaq Capital Market under the ticker “BDMD.”
Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
Get started
Create a free account to read the full story.